Anthem Biosciences Limited (NSE:ANTHEM) held its Q1 FY27 earnings conference call on July 22, 2026, detailing financial performance and operational updates. The company reported consolidated revenues of Rs. 418 crores, with a profit after tax of Rs. 120 crores.
Key Highlights
- Consolidated revenues for Q1 FY27 were reported at Rs. 418 crores.
- The CRDMO business contributed 81.5% of total revenues, amounting to Rs. 341 crores.
- Specialty Ingredients accounted for 18.5% of revenues, generating Rs. 78 crores.
- EBITDA for the quarter stood at Rs. 176 crores, with a margin of 39.6%.
- Profit after tax (PAT) was Rs. 120 crores, reflecting a PAT margin of 27.1%.
- Net cash position as of June 30, 2026, was Rs. 1,720 crores.
- Management emphasized strong underlying demand, with a significant order book for the upcoming quarters.
About the Company
Anthem Biosciences Limited (NSE:ANTHEM) is a leading biopharmaceutical company based in India, specializing in contract research and development as well as manufacturing services. The company primarily operates in the pharmaceutical sector, providing services in custom synthesis and specialty ingredients. With a strong focus on innovation, Anthem aims to meet the evolving needs of its clients across the globe.
Announcement in Detail
The earnings call on July 22, 2026, revealed that Anthem Biosciences achieved consolidated revenues of Rs. 418 crores for Q1 FY27. The CRDMO segment was the primary revenue driver, contributing Rs. 341 crores, while the Specialty Ingredients segment added Rs. 78 crores. The EBITDA for the quarter was reported at Rs. 176 crores, resulting in an EBITDA margin of 39.6%. The profit after tax was Rs. 120 crores, with a PAT margin of 27.1%.
Management noted that the company’s net cash position stood at Rs. 1,720 crores as of June 30, 2026. They highlighted that revenue growth was influenced by timing shifts in deliveries to key customers, with a strong order book expected to drive performance in the latter half of the year. The management remains committed to sustaining revenue growth and improving margins through cost efficiencies and productivity enhancements.
Impact on Investors
Investors will note that the reported revenue figures reflect strong demand in the CRDMO segment, which may indicate a positive outlook for future earnings. The disclosed financial metrics, including a strong EBITDA margin and a healthy net cash position, suggest that the company is well-positioned to navigate market challenges and capitalize on growth opportunities.
Furthermore, the management's emphasis on a strong order book, which is already 60% filled, indicates that investors can expect continued revenue generation in the upcoming quarters. The focus on improving operational efficiencies may also enhance profitability, benefiting shareholders in the long term.
Sector / Market Context
The biopharmaceutical sector in India is experiencing significant growth, driven by increasing demand for contract research and manufacturing services. According to industry reports, the Indian biopharmaceutical market is projected to reach USD 100 billion by 2025, fueled by rising investments in research and development. This growth presents opportunities for companies like Anthem Biosciences to expand their market share and enhance service offerings.